diagnosing & managing sepsis syndrome:
DESCRIPTION
Diagnosing & Managing Sepsis Syndrome: . The Emerging Role of Bedside Analyte Testing. Continuing Education Credit. Date of Release: 6/29/2011 Date of Expiration: 6/29/2013 Estimated time to complete this educational activity: 1 hour. Continuing Education Credit. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/1.jpg)
Diagnosing & Managing Sepsis Syndrome:
The Emerging Role of Bedside Analyte Testing
![Page 2: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/2.jpg)
Continuing Education Credit
Date of Release: 6/29/2011Date of Expiration: 6/29/2013
Estimated time to complete this educational activity: 1 hour
![Page 3: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/3.jpg)
Continuing Education Credit
• Nursing - Educational Review Systems is an approved provider of continuing education in nursing by ASNA, an accredited provider by the ANCC/Commission on Accreditation. Provider #5-115. This program is approved for one (1.0) hour. Educational Review Systems is also approved for nursing continuing education by the State of California and the District of Columbia.
• Physicians - This program has been reviewed and is acceptable for up to one (1.0) prescribed credit hour by the American Academy of Family Physicians. AAFP prescribed credit is accepted by the AMA as equivalent to AMA PRA Category I for the AMA Physicians‘Recognition Award. When applying for the AMA PRA, prescribed hours earned must be reported as prescribed hours, not as Category I.
• Respiratory Therapy - This program has been approved for 1 contact hours Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063 Course # 213078000
![Page 4: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/4.jpg)
Statement of Need
Sepsis kills more than 210,000 Americans each year and is becoming more common, especially in the hospital. Sepsis is a medical emergency that can be difficult to define, diagnose, and treat, but every minute counts in the effort to save lives. This learning activity will describe how bedside analyte testing could aid therapeutic decision making and improve the prognosis for patients with sepsis.
![Page 5: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/5.jpg)
Intended Audience
The primary audience for this learning activity are health care professionals (physicians and nurses) who are involved in the testing, diagnosis, treatment, and management of sepsis and are interested in the role of biomarkers to improve the care forthese patients.
![Page 6: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/6.jpg)
Learning Objectives
1. Discuss the scope of sepsis morbidity and mortality.
After completing this activity, the participant should be able to:
2. Describe the role of sepsis biomarkers in screening, diagnosis, risk stratification, and monitoring of response to therapy in sepsis.
3. List factors to be considered when evaluating sepsis testing and results.
4. Identify situations where point-of-care analyte testing might benefit patients with a suspected or confirmed diagnosis of sepsis.
5. Apply information to assist in the identification and treatment of patients with sepsis and improve patient outcomes.
![Page 7: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/7.jpg)
Medical AdvisementWe would like to acknowledge the following medical experts
who served as advisors to this educational program:
Emanuel P. Rivers, MD, MPH
Thomas Ahrens, DNS, RN, PhD Arthur P. Wheeler, MD
Jill A. Sellers, BSPharm, PharmD
![Page 8: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/8.jpg)
Disclosures
Thomas Ahrens, DNS, RN, PhD No financial relationships to disclose.
Emanuel P. Rivers, MD, MPH No financial relationships to disclose.
Jill A. Sellers, BSPharm, PharmD No financial relationships to disclose.
Arthur P. Wheeler, MD No financial relationships to disclose.
![Page 9: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/9.jpg)
Introduction to Sepsis
Definition, Etiology, Morbidity and Mortality
![Page 10: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/10.jpg)
Definition of Sepsis
• Sepsis
ACCP/SCCM Consensus Conference. Crit Care Med. 1992;20(6):864-74.
– Systemic response to infection
– Manifested by two or more SIRS criteria as a result of proven or suspected infection• Temperature ≥ 38C or ≤ 36C
• HR ≥ 90 beats/min
• Respirations ≥ 20/min
• WBC count ≥ 12,000/mm3 or ≤ 4,000/mm3
or > 10% bands
• PaCO2 < 32 mmHg
![Page 11: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/11.jpg)
Case Study
![Page 12: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/12.jpg)
Case Study: Mr. Z
• He tells you “My tooth is killing me! You can pull it if you need to. I feel like it is going to explode.”
• His tooth pain is severe and he cameto the emergency department since he could not see his dentist until themorning. He has drainage from tooth #20, for which a culture has been obtained and sent to the lab.
• Mr. Z is a 47 year-old male who was admitted to the emergency department. He is complaining of a toothache that has been present for 7 days.
![Page 13: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/13.jpg)
Case Study: Mr. Z
• He is started on Cefoxitin (Mefoxin®) 2 g IV q6h.
• Mr. Z is alert and oriented.
• He has a history of hypertension and had a hemorrhagic stroke 10 years ago but has had no major health issues since this time.
• His heart and lung sounds are normal and his skin is cool and moist. He has good capillary refill, abdomen soft and non-tender.
![Page 14: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/14.jpg)
Case Study: Mr. Z
AdmissionHeart Rate 111
Temperature 38.7
SPO2 0.96
NIBP 128/88 (101)
Respiratory Rate 22
Questions1) Does Mr. Z have signs of sepsis?
Yes2) What is a blood test that would be useful?
Lactate
SPO2: Pulse oximetry oxygen saturation; NIBP: Non-invasive blood pressure
![Page 15: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/15.jpg)
Case Study: Mr. Z
AdmissionHeart Rate 111Temperature 38.7SPO2 0.96NIBP 128/88 (101)Respiratory Rate 22Serum Lactate 3.5
After 20 mg/kg normal saline (10 minutes)
Heart Rate 104Temperature 38.6
SPO2 0.96NIBP 130/88 (102)Respiratory Rate 22
![Page 16: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/16.jpg)
Case Study: Mr. Z
After 4 HoursHeart Rate 88Temperature 38.1SPO2 0.98
NIBP 133/78 (94)Respiratory Rate 17Serum Lactate 1.8
• Often, vital signs are normal when lactates are elevated.
• The use of the lactate allowed the clinician to better evaluate the seriousness of the situation.
• If the lactate had remained elevated, more fluids could have been given.
• A decrease in lactate shows improved perfusion.
![Page 17: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/17.jpg)
Sepsis is Serious.
• Sepsis is a serious medical condition caused by an overwhelming immune response to infection.
http://www.nigms.nih.gov/Education/factsheet_sepsis.htm
• Complex chain of events:– Inflammatory and anti-inflammatory processes
– Humoral and cellular reactions
– Circulatory abnormalities
• Results in impaired blood flow, which damages organs by depriving them of nutrients and oxygen.
![Page 18: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/18.jpg)
The Intracellular Immune Response to Infection
Adapted from Holmes CL, Russell JA, Walley KR. Chest. 2003;124:1103-15.
![Page 19: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/19.jpg)
Symptoms of Sepsis
• Sepsis can begin in different parts of the body and can have many different symptoms.
• Rapid breathing and a change in mental status, may be the first signs of sepsis.
• Other symptoms include:
– Chills/hypothermia
– Decreased urination
– Tachycardia
– Nausea and vomiting
– Fever
![Page 20: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/20.jpg)
Clinical Manifestations of ShockDelirium and Encephalopathy
Acute Lung Injury or ARDS Oliguria
Anuria CreatinineMetabolic acidosis
Platelets PT/APTT Protein C D-dimer
Adrenal Dysfunction
Altered Glucose Metabolism
Jaundice Enzymes Albumin PT
Gut Dysfunction
Hyperpyrexia or Hypothermia
ARDS: Acute respiratory distress syndrome; PT: Prothrombin time; APTT: Activated partial thromboplastin time
![Page 21: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/21.jpg)
The Sepsis Continuum
Adapted from Bone RC, Balk RA, Cerra FB et al. Chest. 1992;101:1644-55.
Infection/Trauma SIRS Sepsis Severe
Sepsis
A clinical response arising from a nonspecific insult, including ≥ 2 of the following:
• Temperature > 38ºC or < 36ºC
• Heart rate > 90 beats/min
• Respiratory rate > 20 breaths/min or PaCO2 < 32 Torr
• WBC > 12,000 cells/mm3, < 4,000 cells/mm3, or > 10% immature
SIRS with a presumed or confirmed infection
Sepsis with ≥ 1 sign of organ failure:
• Cardiovascular (refractory hypotension)
• Renal
• Respiratory
• Hepatic
• Hematologic
• CNS
• Unexplained metabolic acidosis
Local or systemic infection or traumatic injury
![Page 22: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/22.jpg)
SevereSepsis
Bone RC, Balk RA, Cerra FB et al. Chest. 1992;101:1644-55.
Trauma
Infection
SepsisOther
Pancreatitis
Burns
SIRS
The Relationship Between SIRS, Sepsis, and Severe Sepsis
![Page 23: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/23.jpg)
Locations for Common Infection
Lungs
Urinary Tract
Abdomen
Vascular Catheters(endovascular)
Appendix
http://www.nigms.nih.gov/Education/factsheet_sepsis.htm
Skin and soft tissue
![Page 24: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/24.jpg)
Microbes• Many different types of microbes can cause sepsis:
http://www.nigms.nih.gov/Education/factsheet_sepsis.htm
CDC/ Matthew J. Arduino CDC/ Robert Simmons
Staphylococcus sp. (Bacteria) Aspergillus sp. (Fungi) Influenza (Virus)
CDC/ Erskine. L. Palmer, PhD; M. L. Martin
• Severe cases often result from a localized infectionbut sepsis can also spread throughout the body.
– Bacteria (most common)
– Fungi
– Viruses
![Page 25: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/25.jpg)
Mortality Rates
• Sepsis remains the leading cause of death in critically ill patients in the United States.
• Each year 750,000 people will develop sepsis.
Angus DC, Linde-Zwirble WT, Lidicker J et al. Crit Care Med. 2001;29(7):1303-10.
National Center for Health Statistics, 2001. American Cancer Society, 2001.
0
50,000
100,000
150,000
200,000
250,000
Deat
hs P
er Y
ear
AIDS SevereSepsis
Breast Cancer
![Page 26: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/26.jpg)
Sepsis Incidence in Men and Women
Martin GS et al. N Engl J Med. 2003;348:1546-54.
1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001
300
200
100
0
MenWomen
Popu
latio
n-A
djus
ted
Inci
denc
e of
Sep
sis
(No.
/100
,000
)
![Page 27: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/27.jpg)
Martin GS, Mannino DM, Eaton S et al. N Engl J Med. 2003;348:1546-54.
1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001
OtherBlackWhite
Popu
latio
n-A
djus
ted
Inci
denc
e of
Sep
sis
(No.
/100
,000
)500
400
300
200
100
0
Sepsis Incidence by Race
![Page 28: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/28.jpg)
Sepsis Incidence in the United States: 2000
Martin GS, Mannino DM, Eaton S et al. N Engl J Med. 2003;348:1546-54. SEER Cancer Statistics Review. National Cancer Institute. www.cancer.gov. 2007. HIV/AIDS Surveillance Report. Centers for Disease Control. 2001;11.Incidence & Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. NHLBI, NIH. 2006. Turabelidze G. J Neurol Sci. 2008;269:158-62.
0
50
100
150
200
250
Sepsis BreastCancer
AcuteMyocardial
Infarction
MultipleSclerosis
LungCancer
ColonCancer
AIDS
Inci
denc
e pe
r 100
,000
![Page 29: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/29.jpg)
Sepsis Morbidity and Mortality
• In severe cases, one or more organs fail.
http://www.nigms.nih.gov/Education/factsheet_sepsis.htm
• Worst case scenario:– Blood pressure drops– Septic shock– Multiple organ system failure– Death
• The number of sepsis cases per year has been on the rise: – Aging population, the increased longevity of people
with chronic diseases, the spread of antibiotic-resistant organisms, an upsurge in invasive procedures and broader use of immunosuppressive and chemotherapeutic agents.
![Page 30: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/30.jpg)
How Do I Decide Who is Really Sick With an Infection?
![Page 31: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/31.jpg)
Sepsis Biomarkers
Use in Diagnosis, Risk, and Response
![Page 32: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/32.jpg)
Utility of Biomarkers
1. Diagnosis/differentiation
– Value of baseline
2. Prognostication
– Value of change over time
3. Following success/failure of therapy
![Page 33: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/33.jpg)
Diagnosis of Sepsis
• Bacteria in the blood or other body fluids– Source of the infection– A high or low white blood cell count– A low platelet count– Low blood pressure– Too much acid in the blood (acidosis)– Altered kidney or liver function
• Biomarkers
![Page 34: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/34.jpg)
• Diagnosis of sepsis and evaluation of its severity is complicated by the highly variable and non-specific nature of signs and symptoms.
Sepsis Biomarkers: Screening
Lever A, Mackenzie I. Br Med J. 2007;335:879–83.
• Distinguishing patients with localized infections or SIRS from those with sepsis is challenging.
• SIRS is not specific to sepsis and can result from other conditions such as acute pancreatitis and immunodeficiencies.
• Biomarkers of sepsis may improve diagnosis and therapeutic decision making.
![Page 35: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/35.jpg)
Sepsis Biomarkers
• More than 170 biomarkers have been assessed for sepsis prognosis and diagnosis
Pierrakos C, Vincent JL. Crit Care. 2010,14:R15.
• Some common biomarkers include:
– White blood cell count
– Procalcitonin (PCT)
– Procoagulant factors– Lactate
– Interleukins and other cytokines
– C-reactive protein (CRP)
![Page 36: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/36.jpg)
Procalcitonin and Accuracy of Diagnosis
Harbarth S, Holeckova K, Froidevaux C et al. Am J Respir Crit Care Med. 2001;164:396-402.
1 - Specificity
1.00
0.75
0.50
0.25
0.00
Sens
itivi
ty
0.00 0.25 0.50 0.75 1.00
Clinical model with PCTAUC: 0.94Clinical model without PCTAUC: 0.77
![Page 37: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/37.jpg)
Procalcitonin Reference Range
Normal subjects < 0.5 pg/ml
Chronic inflammatory processes and autoimmune diseases < 0.5 pg/ml
Viral infections < 0.5 pg/ml
Mild to moderate localized bacterial infections < 0.5 pg/ml
SIRS, multiple trauma, burns 0.5 – 2 pg/ml
Severe bacterial infections, sepsis, multiple organ failure
> 2 pg/ml(often 10 – 100 pg/ml)
ACCP/ Society of Critical Care Medicine Consensus Conference. Crit Care Med. 1992;20:864-74. Harbarth S, Holeckova K, Froidevaux C et al. Am J Respir Crit Care Med. 2001;164:396-402. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Lancet. 2004;363:600-7.
![Page 38: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/38.jpg)
Annane D, Sebille V, Troche G et al. J Am Med Assoc. 2000;283:1038-45.
Survival Curves in Severe Sepsis and Septic Shock: Baseline Cortisol and Post-ACTH
Prob
abili
ty o
f Sur
viva
l
0
Basal Plasma Cortisol Level 34 g/dL, max > 9 g/dL
Basal Plasma Cortisol Level 34 g/dL, max 9 g/dL orBasal Plasma Cortisol Level > 34 g/dL, max > 9 g/dL
Basal Plasma Cortisol Level > 34 g/dL, max 9 g/dL
1.00
0.80
0.60
0.40
0.20
0 7 14 21 28
Time (Days)
![Page 39: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/39.jpg)
Lobo SM, Lobo FR, Bota DP et al. Chest. 2003;123:2043-9.
CRP Levels Correlate With Mortality and Organ Failure in Sepsis
30
20
10
0
30
20
10
0
*
* p < 0.05
Number of Organ Failures
0 1 2 3 > 4(116/115) (111/110) (56/56) (20/19) (4/4)
Day 0 Day 2C
RP
mg/
dL
CR
P m
g/dL
CRP Day 0CRP Day 2 Non-Survivors
Survivors
p = 0.002p = 0.001
Survivors vs. Non-Survivors
![Page 40: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/40.jpg)
Lactic Acidosis
Mizock BA, Falk JL. Crit Care Med. 1992;20:80-95.
Glycogen
Glucose Pyruvate
Lactate
CitricAcidCycle
CO2
H2O
(Cytoplasm) (Mitochondria)
Anaerobic Glycolysis
1 Glu + 2 ADP + 2 Pi
2 Lactate + 2 ATP
1 Glu + 6 O2 + 38 ADP + 38 Pi
6 CO2 + 6 H20 + 38 ATP
O2
Aerobic Glycolysis
![Page 41: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/41.jpg)
Diagnostic and Therapeutic Markers
SvO2
60-80% Normal50% Lactic Acidosis (≥ 4 mmol/L)
80
60
40
![Page 42: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/42.jpg)
38-40%
28 day in-hospital mortality Death within 3 days
Lactate1
30
25
20
15
10
5
00-2.4 2.5-3.9 > 4.0
% o
f Mor
talit
y R
ate
% o
f Mor
talit
y R
ate
0-2.4 2.5-3.9 > 4.0N = 827 N = 238 N = 112
Initial Lactate (mmol/L)2
50
40
30
20
10.0
0.0
Serum Lactate as a Predictor of Mortality
1 Trzeciak S, Dellinger RP, Chansky ME et al. Intensive Care Med. 2007;33:970-7.2 Shapiro NI, Howell MD, Talmor D et al. Ann Emerg Med. 2005; 45:524-8.
28%
![Page 43: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/43.jpg)
Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160.
Prognostic Value of Serum Lactate
![Page 44: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/44.jpg)
Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160.
Serum Lactate as a Predictor of Mortality
Mea
n La
ctat
e Le
vel (
mm
ol/L
)7
6
5
4
3
2
1
0
Arrival Scene (T1) Emergency Department (T2)
Non-survivalSurvival
p = 0.001p < 0.001
![Page 45: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/45.jpg)
Adapted from Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160.
8/66 (12%)
Mortality
24/58 (41%)
Mortalityp < 0.001
7 Missing (4 Died)
11 Missing (0 Died)
First Lactate Measurement
Second Lactate Measurement
N = 55
8/54 (15%)
Mortality
0/1(0%)
Mortality
p = 1.00
N = 51
2/14 (14%)
Mortality
18/37(49%)
Mortality
p = 0.025
N = 106
10/68 (15%)
Mortality
18/38 (47%)
Mortalityp < 0.001
N = 124
< 3.5 mmol/l ≥ 3.5 mmol/l
< 3.5 mmol/l ≥ 3.5 mmol/l < 3.5 mmol/l ≥ 3.5 mmol/l
< 3.5 mmol/l ≥ 3.5 mmol/l
Second Lactate Cumulative
Value of Blood Lactate Levels
![Page 46: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/46.jpg)
Jansen TC, van Bommel J, Mulder PG et al. Crit Care. 2008,12:R160.
Mor
talit
y (%
)
SBP (mmHg)Lactate (mmol/l)
< 100> 100
> 3.5
< 3.5
60
50
40
30
20
10
0
Lactate, SBP, and Mortality
![Page 47: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/47.jpg)
Serum Lactate and Mortality in Severe Sepsis
• Initial serum lactate evaluated in 839 adults admitted with severe sepsis.
Mikkelsen ME, Miltiades AN, Gaieski DF et al. Crit Care Med. 2009;37:1670-7.
Low Int High
ShockNon-Shock
28-D
ay M
orta
lity
(%)
504540353025201510
50
p < 0.001
p = 0.001
p = 0.022
p = 0.024• High initial serum
lactate associated with ↑ mortality regardless of presence of shock or MODS.
Low Int High
![Page 48: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/48.jpg)
Improving Lactate a Good Prognostic Sign
Bakker J, Gris P, Coffernils M et al. Am J Surg. 1996;171:221-6.
8
6
4
2
0
INITIAL +8h +16h +24h FINALTime
Lact
ate
(mm
ol/L
)
Survivors
Non-survivorsp < 0.05p < 0.05
p < 0.01
![Page 49: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/49.jpg)
Sepsis is No Longer Just an ICU Disease
Levy MM, Dellinger RP, Townsend SR et al. Crit Care Med. 2010;38:367-74.
![Page 50: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/50.jpg)
You have to go to the disease instead of waiting for it to come to you!
Hospital Origin and Mortality
Origin Mortality
Surviving Sepsis Campaign. http://ssc.sscm.org.
ED 52.4% 27.6%ICU 12.8% 41.3%Wards 34.8% 46.8%
![Page 51: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/51.jpg)
Risk Stratification of Sepsis
Surviving Sepsis Campaign. http://ssc.sscm.org.
Hypotension, vasopressors 36.7%
Lactate > 4 mmol/L only 30.0%
SBP < 90 mmHg and lactate > 4 mmol/L 46.1%
![Page 52: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/52.jpg)
Sepsis Testing and Results
Guidelines, Algorithms, and Protocols
![Page 53: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/53.jpg)
• Blood gases
Factors to Consider When Evaluating Sepsis
• Electrolytes
• Glucose
• Hematocrit
• Lactate
![Page 54: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/54.jpg)
Sepsis Resuscitation Bundle
The Sepsis Resuscitation Bundle is published by the Surviving Sepsis Campaign and is used by multiple hospitals across the country.
The goal is to perform all indicated tasks 100% of the time within the first 6 hours of identification of severe sepsis.
Surviving Sepsis Campaign. http://ssc.sscm.org.
![Page 55: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/55.jpg)
Sepsis Resuscitation Bundle
Surviving Sepsis Campaign. http://ssc.sscm.org.
3. Administer broad-spectrum antibiotic, within 3 hours of emergency department (ED) admission and within 1 hour of non-ED admission.
2. Obtain blood cultures prior to antibiotic administration.
1. Measure serum lactate.
4. In the event of hypotension and/or a serum lactate > 4 mmol/L:a. Deliver an initial minimum of 20 ml/kg of crystalloid or an equivalent.
b. Apply vasopressors for hypotension not responding to initial fluid resuscitationto maintain mean arterial pressure (MAP) > 65 mmHg.
5. In the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate > 4 mmol/L:a. Achieve a central venous pressure (CVP) of > 8 mmHg.
b. Achieve a central venous oxygen saturation (ScvO2) > 70% or mixed venous oxygen saturation (SvO2) > 65%.
![Page 56: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/56.jpg)
1. Administer low-dose steroids for septic shock in accordance with a standardized ICU policy. If not administered, document why the patient did not qualify for low-dose steroids based upon the standardized protocol.
Sepsis Management Bundle
Efforts to accomplish these goals should begin immediately, but these items may be completed within 24 hours of presentation for patients with severe sepsis or septic shock.
The tasks are:
2. Administer recombinant human activated protein C (rhAPC) in accordance with a standardized ICU policy. If not administered, document why the patient did not qualify for rhAPC.
3. Maintain glucose control > 70 mg/dL, but < 150 mg/dL.
4. Maintain a median inspiratory plateau pressure (IPP) < 30 cm H2O for mechanically ventilated patients.
Surviving Sepsis Campaign. http://ssc.sscm.org.
![Page 57: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/57.jpg)
Point-of-Care Analyte Benefits
• A 2010 study published in the Journal of Emergency Medicine found that point-of-care testing provided a reliable and feasible way to measure serum lactate at the bedside.1
1 Shapiro NI, Fisher C, Donnino M et al. J Emerg Med. 2010;39:89-94.2 Montassier E, Batard E, Segard J et al. Am J Emerg Med. 2010. Epub ahead of print.3 Martin MJ, FitzSullivan E, Salim A et al. Am J Surg. 2006;191:625-30.4 Moore CC, Jacob ST, Pinkerton R et al. Clin Infect Dis. 2008;46:215-22.
• Point-of-care lactate is useful in the diagnosis of sepsis at the bedside
– Recommended for institutions where clinical decisions are limited by lack of laboratory infrastructure or reliability.4
• Base excess (BE)– Some studies suggest BE is an accurate marker for the
prediction of elevated lactate in the emergency department (ED).2
– Some studies also show poor correlation due to effects of other conditions.3
![Page 58: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/58.jpg)
• pH, pCO2, pO2, lactate, Na, K, iCa, Glu, Hct (plus calculated values TCO2, HCO3, BE, sO2, Hb)
• Single-use, self-calibrating, 100-150 uL WB sample
Point-of-Care Analyte Testing
*unique market features
• Requires only room temperature storage*
• Analytes on a single test card
• Bar-coded for patient safety
• Low-cost test cards
– Cant use expired cards*
– Smart card technology
– < $ than benchtop systems
![Page 59: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/59.jpg)
Turnaround Time
• Serum lactate must be available with rapid turnaround time (within minutes) to effectively treat severely septic patients.
http://www.survivingsepsis.com/bundles/individual_changes/serum_lactate.www.emcrit.org/wp-content/uploads/lactate-faq.pdf.
• An arterial blood gas analyzer located in the clinical laboratories usually accomplishes this.
• Hospitals should invest in adequate equipment in to meet present standards of care for septic patients.
• If a central analyzer is not efficient in a particular hospital setting, point-of-care analyzers should be evaluated for faster turnaround time.
![Page 60: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/60.jpg)
Time and Cost for Measuring Blood Lactate
Chiron Accusport® Central Laboratory
Time of transportation (min) -- -- 9.6 ± 3.8
Time for results (min) 1 1 85 ± 35
Time for results (range) 1-10 1 45-168
Hardware Electrodes: 4 x $134Total: $536 Device: $156 --
Reagents --Test strip: $1.22Quality Control Bottle: $11.10
--
Costs for 197 samples $536 $248 $493
Costs of transportation of one sample -- -- $3.61
Boldt J, Kumle B, Suttner S et al. Acta Anaesthesiol Scand. 2001;45:194–9.
![Page 61: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/61.jpg)
Sepsis Treatment Guidelines
• Antibiotic therapy
Surviving Sepsis Campaign. http://ssc.sscm.org.
– Begin intravenous antibiotics as early as possible
• Always within the first hour of recognizing severe sepsis (1D) and septic shock. (1B)
– Broad-spectrum
• One or more agents active against likely bacterial/fungal pathogens and with good penetration into presumed source. (1B)
– Reassess antimicrobial regimen daily to optimize efficacy, prevent resistance, avoid toxicity, & minimize costs. (1C)
– Consider combination therapy in Pseudomonas infections. (2D)
![Page 62: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/62.jpg)
Sepsis Treatment Guidelines
• Antibiotic therapy
Surviving Sepsis Campaign. http://ssc.sscm.org.
– Consider combination empiric therapy in neutropenic patients. (2D)
– Combination therapy no more than 3-5 days and de-escalation following susceptibilities. (2D)
– Duration of therapy typically limited to 7-10 days
• Longer if response slow, undrainable foci of infection, or immunologic deficiencies. (1D)
– Stop antimicrobial therapy if cause is found to be non-infectious. (1D)
![Page 63: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/63.jpg)
Glycemia Control 80-110
Semi-recumbent
Position
Lactate POC (< 15’) Fluid Bolus
SIRS 2 Criteria• T > 38° or < 36°• HR > 90• RR > 20 or PaCO2 32 mmHg• WBC > 12 K or < 4 K; Bands > 10%Sepsis
No
Yes
CVP < 8
CVP > 15 + MAP > 110
MAP > 110
MAP < 65
No
NS 500 cc IVB until CVP > 8
NTG 10-60 mcg/min until CVP < 12 or MAP < 110
Norepinephrine 2-20 mcg/min or Dopamine 5-20 mcg/kg/min
NTG 10-60 mcg/min until MAP < 90 or Hydralazine 10-40 mg IV
Transfuse PRBC
Dobutamine 2.5-20 mcg/kg/min
ScvO2 < 70% Hgb < 10
ScvO2 < 70%
• CVP 8-12• MAP 65-110• ScvO2 > 70%• Lactate improved
Iden
tific
atio
n A
bs
Rap
id
CV
EGD
TB
undl
ed T
hera
pies
Preload
Afterload
Central Venous Oxygen
Content
Goals Achieved
?
APACHE III > 25
Activated Protein C
Organic Dysfunction
SBP < 90 p bolus Lactate > 4
Central Venous Arterial Line Access (< 2°)
Initiate Sepsis Bundle
Mechanical Ventilation
Labs Cultures
Antibiotics (< 4°)
Severe Sepsis/ Septic Shock
SIRS + Suspected Infection
ScvO2
Hgb
Rivers EP. N Engl J Med. 2001;345:1368-77.
CCF Sepsis Flowchart
![Page 64: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/64.jpg)
Applications
Identification, Treatment, and Outcomes
![Page 65: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/65.jpg)
Are any two of the following SIRS criteria present and new to the patient?
Heart rate > 90 beats/min Respiratory rate > 20/min
Temperature < 36.0 or > 38.3C Acutely altered mental state
Blood glucose > 7.7 mmol/L (in absence of diabetes) White cell count < 4 or > 12 x 109/L
Is there a clinical suspicion of new infection?Cough/sputum/chest pain DysuriaAbdominal pain/distension/diarrhea Headache with neck stiffnessLine infection Cellulitis/wound/joint infectionEndocarditis
Is there evidence of any organ dysfunction?Systolic BP < 90/mean < 65 mmHg Urine output < 0.5 mL/kg/h for 2 hLactate > 2 mmol/L after initial fluids Creatinine > 177 umol/LINR > 1.5 or aPTT > 60 s Platelets < 100 x 109/LBilirubin > 34 umol/L SpO2 > 90% unless O2 given
Identification of Sepsis
If YES, patient has SIRS
If YES, patient has Sepsis
If YES, patient has Severe Sepsis
Daniels R. J Antimicrob Chemother. 2011;66(Suppl 2):ii11–ii23.
![Page 66: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/66.jpg)
Treatment of Patients With Sepsis
• Early goal-directed therapy: standard operating procedure– Apply with critical care/sepsis team if patient remains hypotensive
or lactate remains high following fluid challenges
Daniels R. J Antimicrob Chemother. 2011;66(Suppl 2):ii11–ii23.
1. Site central venous catheter using ultrasound guidance where practicable, according to proper procedures for infection control
2. If central venous pressure (CVP) < 8 mmHg, give further fluid challenges to achieve a target CVP of > 8 mmHg (> 12 mmHgif ventilated) unless the patient shows signs of fluid overload
3. If patient remains hypotensive, start a norepinephrine infusion to target SBP > 90 mmHg or MBP > 65 mmHg.
![Page 67: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/67.jpg)
Improve Patient Outcomes
• Lactate clearance is associated with improved patient outcome.
Nguyen HB, Rivers EP, Knoblich BP et al. Crit Care Med. 2004;32(8):1637-42.Afessa B, Keegan MT, Schramm GE et al. Crit Care Med. 2011;15(Suppl 1): P286. Boldt J, Kumle B, Suttner S et al. Acta Anaesthesiol Scand. 2001;45:194–9.
• Point-of-care measurements of lactate are faster than central laboratories.
– May be beneficial for serial measurements.
• Lactate measurement is associated with increased risk of death independent of other aspects of sepsis bundle guidelines.
![Page 68: Diagnosing & Managing Sepsis Syndrome:](https://reader038.vdocuments.us/reader038/viewer/2022110105/56816978550346895de16dbd/html5/thumbnails/68.jpg)
Conclusion